ストックスクリーナーアプリを入手
9.25
3.65%
-0.35
アフターアワーズ：
9.25
前日終値:
$9.60
開ける：
$8.6
24時間の取引高:
640.31K
Relative Volume:
1.21
時価総額：
$7.75M
収益：
-
当期純損益:
$-67.28M
株価収益率:
-0.0977
EPS:
-94.66
ネットキャッシュフロー:
$-9.80M
1週間 パフォーマンス:
+120.24%
1か月 パフォーマンス:
+105.10%
6か月 パフォーマンス:
+39.10%
1年 パフォーマンス:
-17.89%
1日の値動き範囲:
$7.90
$9.89
1週間の範囲:
$4.07
$13.20
52週間の値動き範囲:
$2.098
$23.01
Portage Biotech Inc Stock (PRTG) Company Profile
PRTG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRTG
Portage Biotech Inc
|
9.25 | 7.75M | 0 | -67.28M | -9.80M | -94.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 33.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Portage Biotech Inc Stock (PRTG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-07 | 開始されました | H.C. Wainwright | Buy |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-02 | 開始されました | B. Riley Securities | Buy |
| 2021-08-19 | 開始されました | Cantor Fitzgerald | Overweight |
Portage Biotech Inc (PRTG) 最新ニュース
Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-High - Asianet Newsable
Small Cap Stocks To Add to Your WatchlistMarch 29th - MarketBeat
Portage Biotech Insider Buyers See Boost After Market Cap Rose US$9.0m - simplywall.st
Promising Biotech Stocks To Watch Now – March 28th - Defense World
Portage Biotech (NASDAQ:PRTG) vs. Cytokinetics (NASDAQ:CYTK) Head-To-Head Survey - Defense World
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
Why Is Portage Biotech Stock Skyrocketing Friday? - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher - Benzinga
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading - Stocks Telegraph
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma - Marketscreener.com
Portage Biotech presents preclinical data for PORT-7 - TipRanks
Portage Biotech reports promising mesothelioma treatment data By Investing.com - Investing.com Australia
Portage Reports 'Promising' Preclinical Results in Mesothelioma - Marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Portage Biotech Announces Promising Preclinical Results for PORT-7 in Mesothelioma - TipRanks
Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7 - MarketScreener
Portage Biotech reports promising mesothelioma treatment data - Investing.com
Portage Biotech stock soars on promising preclinical data - Investing.com
Portage Biotech stock soars on promising preclinical data By Investing.com - Investing.com Canada
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times
Game-Changing Mesothelioma Treatment: New Drug Achieves 90% Tumor Reduction in Latest Study - Stock Titan
Portage Biotech Inc. Announces New Director Compensation Plan and Stock Option Grants - TipRanks
Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6 - Nasdaq
Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments - Marketscreener.com
Portage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy Approach - TipRanks
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial - The Manila Times
Major Milestone: Portage Biotech's Novel Cancer Drug Enters Final Trial Phase - StockTitan
Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big Opportunity - MSN
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange - Newsfile
Portage Biotech granted Nasdaq compliance extension By Investing.com - Investing.com Nigeria
Portage Biotech receives extension from Nasdaq to attain listing compliance - MSN
Portage Biotech granted Nasdaq compliance extension - MSN
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - The Manila Times
Portage Biotech Granted Nasdaq Compliance Extension - TipRanks
Portage Biotech, Inc. Receives Extension to Regain Nasdaq Compliance Following Acceptance of Compliance Plan - Nasdaq
Nasdaq Grants Portage Biotech Critical 18-Month Lifeline to Secure Exchange Status - StockTitan
Hepatocellular Carcinoma Pipeline 2024: Latest FDA Approvals, - openPR
What is the investor’s view on Portage Biotech Inc (PRTG)? - US Post News
Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement - Stocks Telegraph
Portage Biotech Announces Completion of $2.15 Million Private Financing - The Manila Times
Portage Biotech Secures $2.15 Million in Private Financing - TipRanks
Portage Biotech, Inc. Completes $2.15 Million Private Placement to Support Corporate Growth - Nasdaq
Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement - StockTitan
Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Here’s What Happened - Defense World
Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc - Marketscreener.com
Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics with New CEO - TipRanks
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company - The Manila Times
Portage Biotech Inc (PRTG) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):